Cogent Biosciences, Inc.

NasdaqGS:COGT Stock Report

Market Cap: US$861.6m

Cogent Biosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Andy Robbins

Chief executive officer

US$7.9m

Total compensation

CEO salary percentage8.3%
CEO tenure4.3yrs
CEO ownershipn/a
Management average tenure4yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Dec 18
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Sep 04
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Inflection Year Directly Ahead

Jun 23

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

May 22
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

Feb 14

Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 27
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 20
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Mar 05
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 18
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Cogent Biosciences: What's Ahead

Sep 13

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Jun 26

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 10
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Cogent Biosciences names new chief legal officer

May 03

What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Mar 17
What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Cogent Biosciences gets Piper Sandler nod on Kiq acquisition

Dec 23

Cogent Biosciences prices upsized $100M equity offering

Dec 02

Cogent Bio launches $60M equity offering, shares down 7%

Nov 30

Cogent Bio reports data from PLX9486 combo trial in GIST patients

Nov 18

Cogent Biosciences EPS misses by $4.91

Nov 09

CEO Compensation Analysis

How has Andy Robbins's remuneration changed compared to Cogent Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$242m

Jun 30 2024n/an/a

-US$227m

Mar 31 2024n/an/a

-US$212m

Dec 31 2023US$8mUS$656k

-US$192m

Sep 30 2023n/an/a

-US$178m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$148m

Dec 31 2022US$4mUS$624k

-US$140m

Sep 30 2022n/an/a

-US$126m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$3mUS$593k

-US$72m

Sep 30 2021n/an/a

-US$163m

Jun 30 2021n/an/a

-US$194m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$18mUS$102k

-US$179m

Compensation vs Market: Andy's total compensation ($USD7.90M) is above average for companies of similar size in the US market ($USD3.23M).

Compensation vs Earnings: Andy's compensation has increased whilst the company is unprofitable.

CEO

Andy Robbins (48 yo)

4.3yrs

Tenure

US$7,898,772

Compensation

Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director at of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Robbins
President4.3yrsUS$7.90mno data
John Robinson
Chief Scientific Officer3.8yrsUS$2.98m0%
$ 0
Jessica Sachs
Chief Medical Officer5.6yrsUS$3.00m0.0012%
$ 10.1k
John Green
CFO & Principal Accounting Officer4.5yrsUS$2.14mno data
Brad Barnett
Chief Technology Officer4.2yrsno datano data
Christi Waarich
Senior Director of Investor Relationsno datano datano data
Evan Kearns
Chief Legal Officer & Corporate Secretary3.7yrsno datano data
Erin Schellhammer
Chief People Officerno datano datano data
Dana Martin
Senior VP of Medical Affairs & Chief Patient Officerno datano datano data
Brad Fell
Senior Vice President of Chemistryno datano datano data
Rachael Easton
VP & Head of Clinical Development2.2yrsno datano data
Ben Exter
Senior VP and Head of Regulatory & Pharmacovigilanceless than a yearno datano data

4.0yrs

Average Tenure

48yo

Average Age

Experienced Management: COGT's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew Robbins
President4.3yrsUS$7.90mno data
Arlene Morris
Independent Director5.5yrsUS$345.49k0%
$ 0
Matthew Ros
Independent Director5.5yrsUS$336.69k0%
$ 0
Todd Shegog
Independent Director3.9yrsUS$345.80k0%
$ 0
Kwok-Kin Wong
Member of Scientific Advisory Boardno datano datano data
Karen Jean Ferrante
Independent Director6.9yrsUS$340.37k0%
$ 0
Michael Vasconcelles
Member of Scientific Advisory Boardno datano datano data
Ryan Corcoran
Member of Scientific Advisory Boardno datano datano data
Christopher Cain
Independent Director4.5yrsUS$341.36k0%
$ 0
Peter Harwin
Independent Chairman of the Board4.5yrsUS$364.55k0%
$ 0
Srdan Verstovsek
Member of Scientific Advisory Boardno datano datano data
Sylvia Adams
Member of Scientific Advisory Board2yrsno datano data

4.5yrs

Average Tenure

58yo

Average Age

Experienced Board: COGT's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 20:57
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cogent Biosciences, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Joel BeattyBaird
David LebowitzCitigroup Inc